THC Memory & Reward Learning Pilot

NCT ID: NCT05116527

Last Updated: 2025-03-17

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-07-07
• Study Completion Date: 2025-12-31

Brief Summary

Tetrahydrocannabidiol (THC) is the psychoactive chemical in cannabis that makes people high. This study aims to dissect acute impairment of various forms of memory and learning by THC in cannabis compared to placebo. Impairment will be assessed via a short cognitive test battery and then subjects will complete four tasks in the fMRI scanner.

Detailed Description

The protocol below is designed to begin dissecting acute impairment of various forms of memory and learning by THC in cannabis compared to placebo, in a 2-session per subject double-blind, random assignment, placebo-controlled counterbalanced design in young to middle-aged adults. The purpose of these experiments is to gather important pilot data to demonstrate proof of principle for a planned NIDA submission of a P50 center application that will examine cannabis's differential effects on the neural circuit underpinnings these various cognitive domains across the lifespan in much more detail. In other words, these pilot data will show NIDA that the investigators' methods and approaches work and are suitable for use in their proposed center grant application. Unlike in the planned P50, in these small-scale pilot studies the investigators are only concerned with comparing these disrupting effects using a single dose of THC versus placebo, without exploration of age, sleep, or sex-related differential effects or of different dose-related effects.

Tasks tapping each of the major cognitive memory-related domains will be performed in the MRI scanner, to reveal the relevant underlying circuitry and its disruption by drug using functional MRI. Although each of the fMRI tasks is already implemented in the investigators' lab in other contexts, the investigators have never studied alteration of the fMRI tasks by THC. Neither have other investigators elsewhere used this approach. It is also important to point out that the dose of active THC to be administered is the same as that already used safely in the investigators' IRB-approved driving studies, one which subjects state subjectively (a blind to actual dose information) makes them feel moderately intoxicated, and similar to the amount that they would consume themselves recreationally.

The study will consist of 3 days (screening visit and 2 dose days). In a randomized, counterbalanced, double-blind study, investigators will administer high THC marijuana or placebo marijuana using paced inhalation through a vaporizer. Following administration, subjects will provide subjectively-rated CNB intoxication using a verbal analog scale, a short cognitive test battery, then complete 4 fMRI paradigms within ~1.5 hours: a) MSDM task, b) MID task, c) RISE task, and d) Treadway Effort/Reward task. These tests will be counterbalanced across subjects and sessions to minimize order and fatigue effects.

Conditions

Marijuana; THC; Cannabis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: QUADRUPLE

Study Groups

High Dose THC

Participants will receive high dose THC.

Group Type: EXPERIMENTAL

Marijuana, Hash, THC, or Grass

Intervention Type: DRUG

Marijuana flower with a high THC content

Placebo THC

Participants will receive placebo THC.

Group Type: EXPERIMENTAL

Placebo

Intervention Type: DRUG

Placebo THC - marijuana flower with no THC content

Interventions

Marijuana, Hash, THC, or Grass

Marijuana flower with a high THC content

Intervention Type: DRUG

Placebo

Placebo THC - marijuana flower with no THC content

Intervention Type: DRUG

Other Intervention Names

Marijuana; THC

Eligibility Criteria

Inclusion Criteria

• 18-55 years old
• Right handed
• CNB use within past 2 years and felt "high" when used
• Able to read, speak, and understand English
• Able and willing to provide written informed consent, and willing to commit to study protocol.

Exclusion Criteria

• Current marijuana tolerance, desire to cut down, or cravings to sue during periods of abstinence.
• Strongly left-handed
• Positive screen for drug or alcohol (except CNB) on test day will result in rescheduling the appointment
• History of adverse effects with CNB
• CNB users who are abstaining
• Report of any psychotic disorder in a first degree relative
• IQ < 80 on the Wechsler Abbreviated Scale of Intelligence
• Inability to comprehend written instructions using the WRAT-4 reading achievement test
• Pregnant, breastfeeding, and ineffective birth control methods.
• Unable or unsafe to have an MRI
• Serious medical, neuro-ophthalmological, or neurological illness (e.g. cancer, seizure disorders, encephalopathy
• History of head trauma with loss of consciousness > 30 minutes or concussion lasting 30 days.
• Focal brain lesion seen on structural MRI
• Any medical/neurological condition that could compromise neurocognitive performance (e.g. epilepsy, multiple sclerosis, fetal alcohol syndrome).
• Anyone deemed unsafe to study personnel for any reason

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Yale University

OTHER

Sponsor Role: collaborator

Hartford Hospital

OTHER

Sponsor Role: lead

Responsible Party

Godfrey Pearlson

Founding Director Olin Neuropsychiatry Research Center; Professor Yale University

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Godfrey Pearlson, M.D

Role: PRINCIPAL_INVESTIGATOR

Yale University

Locations

Hartford Hospital

Hartford, Connecticut, United States

Countries

United States

Other Identifiers

HHC-2021-0195

Identifier Type: -

Identifier Source: org_study_id